Search

everythinglearnresearchcommunity

for

Search:↓

Targeting specific T cells may help treat alopecia areata.

The Tru9I variant in the VDR gene may influence alopecia areata risk and vitamin D levels.

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

Improving blood vessel health and controlling uric acid may help manage alopecia areata.

BST2 is highly expressed in certain immune cells in alopecia areata, suggesting a role in the disease.

Different γδ T cell types have unique roles in causing alopecia areata.

Azathioprine can cause unexpected hair loss and severe bone marrow issues, so careful monitoring is needed.

Certain NK cell changes in blood may indicate alopecia areata progression.

SOX10 in hair follicles is linked to inflammation in alopecia areata.

Increasing regulatory T cells may help treat alopecia areata by reducing autoimmunity and promoting hair growth.

Lower survivin levels in blood are linked to more severe and progressing alopecia areata.

New imaging technology can show up to 40 different markers in hair loss tissue, helping to understand hair disease better.

Human Beta Defensin 1 levels do not predict the risk or severity of Alopecia Areata.

Systemic corticosteroids can help treat rapidly spreading vitiligo but require more research for safer use.

Double-stranded RNA causes inflammation in hair follicle cells, which may help understand and treat alopecia areata.

Scientists have found specific genes linked to different hair loss conditions, which could lead to new treatments.

Faulty inflammasome activation may lead to autoimmune skin diseases and could be a target for new treatments.

A new method helps diagnose alopecia areata using specific gene markers and could guide targeted treatments.

A new nanozyme using EGCG and L-arginine boosts hair growth by safely increasing beneficial oxidative stress.

IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.

People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Blocking JAK3 signaling can reverse hair loss from alopecia areata.

IL-4 gene variation may increase the risk of alopecia areata in Turkish people.

Langsat fruit has health benefits like fighting malaria, bacteria, and aging, but its peel is toxic.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.